September 10, 2017 05:59 AM EDT

#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage

MADRID — Eli Lilly came to ESMO with an eye to distinguishing abemaciclib as it prepares to launch its CDK 4/6 cancer drug against …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ES­MO17: Eli Lil­ly sets the stage for a CDK 4/6 show­down with Pfiz­er, No­var­tis — but not ex­act­ly to its ad­van­tage